Smithfield Trust’s Ligand Pharmaceuticals LGND Stock Holding History

Smithfield Trust’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26	Closed	-$2K	–	982
2019 Q4	$2K	Hold	26	–	–	﹤0.01%	910
2019 Q3	$2K	Hold	26	–	–	﹤0.01%	949
2019 Q2	$2K	Hold	26	–	–	﹤0.01%	933
2019 Q1	$2K	Hold	26	–	–	﹤0.01%	900
2018 Q4	$2K	Hold	26	–	–	﹤0.01%	886
2018 Q3	$4K	Hold	26	–	–	﹤0.01%	847
2018 Q2	$3K	Hold	26	–	–	﹤0.01%	916
2018 Q1	$3K	Hold	26	–	–	﹤0.01%	926
2017 Q4	$2K	Buy	+26	New	+$2.25K	﹤0.01%	1038

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Smithfield Trust's LGND Position: Q1 2020 in Review

Smithfield Trust sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 26 shares — an estimated $2K sold.

Smithfield Trust first reported a position in LGND in Q4 2017 and held it in 9 quarters. The position peaked at $4K in Q3 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

Smithfield Trust reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Smithfield Trust sold 26 Ligand Pharmaceuticals shares in Q1 2020, an estimated $2K.
Smithfield Trust first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Smithfield Trust's Ligand Pharmaceuticals position peaked at $4K in Q3 2018.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Smithfield Trust's 13F filing for Q1 2020, filed 5 May 2020.